Navigation Links
Lumeda Announces Formation of its Scientific Advisory Board

Lumeda Inc. (“Lumeda”), a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the formation of its Scientific Advisory Board with the appointment of a panel of medical and scientific experts who will provide critical medical, scientific, and strategic advice to support company development and introduction of its PDT products to the clinic. The three charter members appointed are:

Dr. Justin D. Blasberg MD, MPH, FACS, Associate Professor of Surgery and Director of Robotic Thoracic Surgery at Yale School of Medicine. As a skilled surgeon, Dr. Blasberg performs the majority of his surgeries in a minimally invasive fashion. He leads a clinical research program on novel imaging techniques for the detection of lung cancer and surgical outcomes research in thoracic surgery.

Dr. Michael M. Conway MD, is a medical executive and Pulmonary Disease and Internal Medicine specialist practicing in Hartford, CT and affiliated with Hartford Hospital. A recognized pulmonary expert with strong regional ties, Dr. Conway brings to Lumeda significant knowledge and expertise in diagnosing and staging of respiratory cancers, and associated standards of care and treatment options.

Dr. Gal Shafirstein DSc, Professor of Oncology and Director of PDT Clinical Research at Roswell Park Comprehensive Cancer Center. Dr. Shafirstein leads PDT translational and clinical research at Roswell Park focused on treatment planning and light dosimetry for interstitial and intraoperative PDT. He is the principal investigator and inventor on the intraoperative PDT innovation for treating lung cancer that Lumeda is commercializing.

“We are very pleased to have such accomplished medical and scientific professionals augment our team to advance this important lung cancer therapy,” according to Paul Sanders, one of the founders of Lumeda. “This advisory group brings a broad range of expertise that is critical to Lumeda’s product design and longer term strategy”.

This panel of medical and PDT science experts was carefully chosen and augments the company photonics engineering and development capabilities to advance its PDT product design for treatment effectiveness and fitness for use in the operating room environment.

About Lumeda:
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related medicine technology :

1. R3 Medical Training Announces Healthcare Sales & Marketing Course Now Enrolling in August for Several Locations
2. Lighthouse Autism Center Announces Strategic Acquisition of Autism Therapy Services
3. SupplyPro Gives Back: SupplyPro Announces the Put Your Money Where Your Mask Is Sales Promotion
4. Touch-A-Life Foundation Announces Sunitha as Global Brand Ambassador
5. ProAct Safety Announces Resource Page for Business Safety Strategies to Deal with COVID-19
6. The Conference Forum Announces Mobile in Clinical Trials Conference Goes Virtual and Addresses Urgent Adoption of Digital Solutions for Clinical Research
7. Gateway for Cancer Research Announces New Grant Program for Clinical Trials Informed by Mobile Technology and Telemedicine
8. M&S Technologies announces an important new product, Web-Based Vision Testing
9. R3 Medical Training Announces Virtual Functional Medicine Course May 28-30th
10. Agency Announces Daily Inspirational Call as Part of Faith Partnership Initiative
11. Allergy Standards Announces the Appointment of Bret Barasch to Lead Sales in the USA
Post Your Comments:
(Date:8/9/2020)... , ... August 09, 2020 , ... ... on sustainable results, today announced that Lydia C. Alexander, MD, has joined the ... medicine specialist, Dr. Alexander will play a vital role in expanding Enara Health’s ...
(Date:8/7/2020)... SEATTLE (PRWEB) , ... August 07, 2020 , ... ... sleep, published a literature review showing how sleep is a mechanism connecting social ... looked at the CDC’s survey of close to 444,000 Americans that draws direct ...
(Date:8/7/2020)... , ... August 07, 2020 , ... ... a blog educating readers on what intensive outpatient programs are and ... and to overcome their addiction, many turn to intensive outpatient programs provided by ...
Breaking Medicine Technology:
(Date:8/5/2020)... , ... August 04, 2020 , ... Today, Power to ... Child Health Programs (AMCHP) with the 2020 Innovation Station Best Practice Award. The One ... and under what circumstances to get pregnant and have a child. One Key Question ...
(Date:8/3/2020)... ... 2020 , ... WorkBook6 – a Tempe, Arizona-based partnership development ... provides a simple and efficient way for Americans over the age of 65 ... important expansion for the insurance marketing ecosystem, and a critical service for seniors ...
(Date:8/3/2020)... CHICAGO and FORT WORTH, Texas (PRWEB) , ... ... ... clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line ... arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). ...
(Date:7/31/2020)... ... July 31, 2020 , ... ... patients to The Dental Studio of Midland for groundbreaking laser dentistry treatment ... result, these patients are able to experience the many advantages of laser dentistry ...
(Date:7/31/2020)... ... 2020 , ... National Association of Chain Drug Stores (NACDS) ... nation’s ongoing preparations for the eventual deployment of COVID-19 vaccines: , “By any ... essential component of vaccine deployment. They will need to be part of the ...
Breaking Medicine News(10 mins):